http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2387693-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-916 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-635 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2000-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b3221653abbbf1030d54cea5c2bc238 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50fd9a670ef5f8d21284d3523d6dafb3 |
| publicationDate | 2001-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2387693-A1 |
| titleOfInvention | Method for monitoring treatment with a parathyroid hormone |
| abstract | The present invention relates to a method for monitoring effects of administration of a parathyroid hormone by determining levels of one or more markers of an activity of this hormone. Suitable markers of bone formation include one or more enzymes indicative of osteoblastic processes of bone formation, preferably bone specific alkaline phosphatase, and/or one or more products of collagen biosynthesis, preferably a procollagen I C-terminal propetide. Suitable markers of bone resorption and turnover include one or more products of collagen degradation, preferably an N-terminal telopeptide (NTX). In addition, methods for concurrently reducing the risk of both vertebral and non-vertebral bone fracture in a male human subject at risk of or having ossteoporosis are also disclosed, involving administration of huma n parathyroid hormone (amino acid sequence 1-34) without concurrent administration of an antiseropositive agent other than vitamin D or calcium. |
| priorityDate | 1999-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 932.